Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans

Research output: Contribution to journalReview article

Abstract

Cutaneous sarcoma is a group of malignant mesenchymal tumors primarily involving the dermis, and it is characterized by extreme clinicopathological heterogeneity. Although its occurrence rate is rare, dermatofibrosarcoma protuberans (DFSP) is one of the most common types of dermal sarcoma. DFSP grows slowly and tends to relapse locally after inadequate resection. There are various histological variants of DFSP tumors and it often mimics benign lesions such as dermatofibroma and scar, which make accurate diagnosis difficult and delayed, and some cases progress to the stage where the tumor is unresectable. Recent advancements in cancer genetics and molecular biology methods have elucidated the COL1A1-PDGFB fusion gene, some novel fusion gene variants and pathways related to DFSP pathogenesis that have resulted in the evolution of cutaneous sarcoma diagnosis and treatment. For example, some clinical studies have confirmed the efficacy of imatinib methylate, an αPDGFR-targeted therapy for unresectable or metastatic DFSP. The present review summarizes recent updates in DFSP research, diagnostics, and treatment.

Original languageEnglish
Article number29
JournalCurrent Treatment Options in Oncology
Volume20
Issue number4
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Dermatofibrosarcoma
Sarcoma
Molecular Biology
Skin
sis Genes
Benign Fibrous Histiocytoma
Neoplasms
Gene Fusion
Delayed Diagnosis
Dermis
Cicatrix
Therapeutics
Recurrence
Research

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

Current Update on the Molecular Biology of Cutaneous Sarcoma : Dermatofibrosarcoma Protuberans. / Iwasaki, Takeshi; Yamamoto, Hidetaka; Oda, Yoshinao.

In: Current Treatment Options in Oncology, Vol. 20, No. 4, 29, 01.04.2019.

Research output: Contribution to journalReview article

@article{68a87a6ee24241d78f3ef109c8c5d76d,
title = "Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans",
abstract = "Cutaneous sarcoma is a group of malignant mesenchymal tumors primarily involving the dermis, and it is characterized by extreme clinicopathological heterogeneity. Although its occurrence rate is rare, dermatofibrosarcoma protuberans (DFSP) is one of the most common types of dermal sarcoma. DFSP grows slowly and tends to relapse locally after inadequate resection. There are various histological variants of DFSP tumors and it often mimics benign lesions such as dermatofibroma and scar, which make accurate diagnosis difficult and delayed, and some cases progress to the stage where the tumor is unresectable. Recent advancements in cancer genetics and molecular biology methods have elucidated the COL1A1-PDGFB fusion gene, some novel fusion gene variants and pathways related to DFSP pathogenesis that have resulted in the evolution of cutaneous sarcoma diagnosis and treatment. For example, some clinical studies have confirmed the efficacy of imatinib methylate, an αPDGFR-targeted therapy for unresectable or metastatic DFSP. The present review summarizes recent updates in DFSP research, diagnostics, and treatment.",
author = "Takeshi Iwasaki and Hidetaka Yamamoto and Yoshinao Oda",
year = "2019",
month = "4",
day = "1",
doi = "10.1007/s11864-019-0628-3",
language = "English",
volume = "20",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Current Update on the Molecular Biology of Cutaneous Sarcoma

T2 - Dermatofibrosarcoma Protuberans

AU - Iwasaki, Takeshi

AU - Yamamoto, Hidetaka

AU - Oda, Yoshinao

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Cutaneous sarcoma is a group of malignant mesenchymal tumors primarily involving the dermis, and it is characterized by extreme clinicopathological heterogeneity. Although its occurrence rate is rare, dermatofibrosarcoma protuberans (DFSP) is one of the most common types of dermal sarcoma. DFSP grows slowly and tends to relapse locally after inadequate resection. There are various histological variants of DFSP tumors and it often mimics benign lesions such as dermatofibroma and scar, which make accurate diagnosis difficult and delayed, and some cases progress to the stage where the tumor is unresectable. Recent advancements in cancer genetics and molecular biology methods have elucidated the COL1A1-PDGFB fusion gene, some novel fusion gene variants and pathways related to DFSP pathogenesis that have resulted in the evolution of cutaneous sarcoma diagnosis and treatment. For example, some clinical studies have confirmed the efficacy of imatinib methylate, an αPDGFR-targeted therapy for unresectable or metastatic DFSP. The present review summarizes recent updates in DFSP research, diagnostics, and treatment.

AB - Cutaneous sarcoma is a group of malignant mesenchymal tumors primarily involving the dermis, and it is characterized by extreme clinicopathological heterogeneity. Although its occurrence rate is rare, dermatofibrosarcoma protuberans (DFSP) is one of the most common types of dermal sarcoma. DFSP grows slowly and tends to relapse locally after inadequate resection. There are various histological variants of DFSP tumors and it often mimics benign lesions such as dermatofibroma and scar, which make accurate diagnosis difficult and delayed, and some cases progress to the stage where the tumor is unresectable. Recent advancements in cancer genetics and molecular biology methods have elucidated the COL1A1-PDGFB fusion gene, some novel fusion gene variants and pathways related to DFSP pathogenesis that have resulted in the evolution of cutaneous sarcoma diagnosis and treatment. For example, some clinical studies have confirmed the efficacy of imatinib methylate, an αPDGFR-targeted therapy for unresectable or metastatic DFSP. The present review summarizes recent updates in DFSP research, diagnostics, and treatment.

UR - http://www.scopus.com/inward/record.url?scp=85062941437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062941437&partnerID=8YFLogxK

U2 - 10.1007/s11864-019-0628-3

DO - 10.1007/s11864-019-0628-3

M3 - Review article

C2 - 30874910

AN - SCOPUS:85062941437

VL - 20

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 4

M1 - 29

ER -